Translate this page into:
Plasmid-Mediated Fluoroquinolone Resistance in Pseudomonas aeruginosa and Acinetobacter baumannii
Address for correspondence: Geetha P. Venkataramana, MSc, Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600116, Tamil Nadu, India (e-mail: gethu16@gmail.com).
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Introduction
Pseudomonas aeruginosa and Acinetobacter baumannii are important pathogens in health care–associated infections. Fluoroquinolone resistance has emerged in these pathogens. In this study, we aimed to determine the occurrence of plasmid-mediated quinolone resistance (PMQR) determinants (qnrA, qnrB, qnrS, aac(6′)-Ib-cr, oqxAB, and qepA) by polymerase chain reaction (PCR) and the transmissibility of plasmid-borne resistance determinants in clinical isolates of P. aeruginosa and A. baumannii.
Materials and Methods
The study included P. aeruginosa (85) and A. baumannii (45) which were nonduplicate, clinically significant, and ciprofloxacin resistant. Antibiotic susceptibility testing was done by disk diffusion method for other antimicrobial agents, namely amikacin, ceftazidime, piperacillin/tazobactam, ofloxacin, levofloxacin, and imipenem. Minimum inhibitory concentration of ciprofloxacin was determined. Efflux pump activity was evaluated using carbonyl-cyanide m-chlorophenylhydrazone (CCCP). The presence of PMQR genes was screened by PCR amplification. Transferability of PMQR genes was determined by conjugation experiment, and plasmid-based replicon typing was performed.
Results
Resistance to other classes of antimicrobial agents was as follows: ceftazidime (86.9%), piperacillin/tazobactam (73.8%), imipenem (69.2%), and amikacin (63.8%). The minimal inhibitory concentration (MIC)50 and MIC90 for ciprofloxacin were 64 and greater than or equal to 256 µg/mL, respectively. There was a reduction in MIC for 37 (28.4%) isolates with CCCP. In P. aeruginosa, 12 (14.1%) isolates harbored qnrB, 12 (14.1%) qnrS, 9 (10.5%) both qnrB and qnrS, 66 (77.6%) aac(6′)-Ib-cr, and 3 (3.5%) oqxAB gene. In A. baumannii, qnrB was detected in 2 (4.4%), 1 (2.2%) harbored both the qnrA and qnrS, 1 isolate harbored qnrB and qnrS, 21 (46.6%) aac(6′)-Ib-cr, and 1 (2.2%) isolate harbored oqxAB gene. Notably, qepA gene was not detected in any of the study isolates. Conjugation experiments revealed that 12 (9.2%) were transferable. Of the transconjugants, seven (58.3%) belonged to IncFII type plasmid replicon, followed by four (33.3%) IncA/C and one (8.3%) IncFIC type.
Conclusion
The plasmid-mediated resistance aac(6′)-Ib-cr gene is primarily responsible for mediating fluoroquinolone resistance in clinical isolates of P. aeruginosa and A. baumannii. The predominant plasmid type is IncFII.
Keywords
aac(6')-Ib-cr
fluoroquinolones
PMQR
Introduction
Fluoroquinolones are synthetic antimicrobial agents with a broad spectrum of activity. They are effective against a wide range of gram-negative and gram-positive pathogenic bacteria. Over the past few years, fueled by their wide use, resistance to fluoroquinolones has raised globally.[1] An important resistance mechanism to fluoroquinolones is described by mutations in the quinolone resistance-determining regions of gyrase and topoisomerase encoding genes.[2] Another well-known fluoroquinolone resistance mechanism is the decreased intracellular drug accumulation by upregulation of efflux pumps or decreased expression of outer membrane porin.[3] The emergence of plasmid-mediated quinolone resistance (PMQR) has been reported since 1998. These are horizontally transferable and are referred to as “PMQR.” The three PMQR genes include: (1) the qnr, (2) aac(6′)-Ib-cr (aminoglycoside acetyltransferase), and (3) oqxAB and qepA (efflux pumps).[4]
The plasmid qnr genes (qnrA, qnrB, and qnrS) encode for proteins of the pentapeptide repeat family that protect DNA gyrase and topoisomerase intravenous from fluoroquinolone inhibition. The aac(6′)-Ib-cr is a bifunctional variant of aminoglycoside acetyltransferase capable of modifying the fluoroquinolones that have an amino nitrogen on the C7 of piperazinyl ring, such as ciprofloxacin and norfloxacin, thereby reducing their activity.[5] Other fluoroquinolones lacking an unsubstituted piperazinyl nitrogen are not affected.[6] The plasmid-mediated qepA efflux pump belongs to the major facilitator superfamily that decreases susceptibility to hydrophilic fluoroquinolones, especially ciprofloxacin.[7] The oqxAB encodes for efflux pumps belonging to the resistance nodulation division family and is a multidrug efflux pump.[8]
Acinetobacter baumannii and Pseudomonas aeruginosa are well recognized representatives of nonfermenting gram-negative pathogens which are responsible for health care-acquired infections. In both species, resistance to fluoroquinolones has been a recognized problem due to their ready ability to acquire resistance determinants.[2] Most studies on prevalence of PMQR genes are focused on Enterobacteriaceae.[9-11] Data on the prevalence of PMQR genes among clinical isolates of P. aeruginosa and A. baumannii are scarce.[12]
The presence of fluoroquinolone resistance genes on plasmid enables their spread to other bacterial species by horizontal gene transfer. The identification of related plasmids associated with specific resistance genes helps track the spread of resistant plasmids. Hence, polymerase chain reaction (PCR)-based replicon typing (PBRT) has been adopted worldwide as the method for plasmid identification and typing.[13]
In this study, we aimed to determine the occurrence of PMQR determinants (qnrA, qnrB, qnrS, aac(6′)-Ib-cr, oqxAB, and qepA) by PCR and the transmissibility of these plasmid-borne resistance determinants in clinical isolates of P. aeruginosa and A. baumannii.
Materials and Methods
Bacterial Isolates
The study included P. aeruginosa (85) and A. baumannii (45) which were nonduplicate, clinically significant and ciprofloxacin resistant (as determined by disc diffusion test) and obtained from clinical specimens of hospitalized patients at university teaching hospital in South India. They were collected over a period of 1 year from July 2014 to June 2015. They were obtained from clinical specimens such as urine (5), exudative samples (66), respiratory secretions (47), and blood stream (12). The isolates were identified up to species level by automated system (VITEK2 GN-card; BioMerieux, Brussels, Belgium) and/or standard biochemical tests.
Antimicrobial Susceptibility Testing
Antibiotic susceptibility testing was done by Kirby–Bauer disc diffusion method for the following antimicrobials: ceftazidime (30 µg), piperacillin/tazobactam (30 µg), imipenem (10 µg), amikacin (30 µg), levofloxacin (5 µg), and ofloxacin (5 µg) (Himedia Laboratories, India). The minimal inhibitory concentration (MIC) of ciprofloxacin was determined by agar dilution technique according to CLSI 2017 guidelines.[14] ATCC Escherichia coli 25922 was used as control for both disc diffusion method and MIC determination.
Phenotypic Detection of Efflux Pump Activity
To detect the presence of efflux pump mechanism, carbonyl-cyanide m-chlorophenylhydrazone (CCCP), the efflux pump inhibitor was added to each Muller–Hinton (MH) agar plate containing 0.125 to 256 μg/mL of ciprofloxacin. The fixed concentration of CCCP in the MH agar was 20 μg/mL. The MIC with CCCP incorporated was determined in twofold serial dilutions as for the antibiotic (CLSI 2017).[14] A plate without antibiotic and containing only CCCP inhibitor was used as control. The criteria for the presence of efflux pump activity was based on a fourfold decrease in MIC of ciprofloxacin on addition of CCCP.[15]
Polymerase Chain Reaction
The DNA of the study isolates was extracted by the boiling method. The amplification of qnr genes (qnrA, qnrB, and qnrS) was performed by multiplex PCR using the cyclic profile: initial denaturation at 94°C for 7 minutes; denaturation at 94°C for 50 seconds, annealing at 53°C for 40 seconds, and elongation at 72°C for 60 seconds, repeated for 35 cycles, and a final extension at 72°C for 5 minutes.[16] The PCR conditions for acc(6′)-Ib-cr were: initial denaturation at 94°C for 7 minutes, denaturation at 94°C for 50 seconds, annealing at 55°C for 40 seconds, and elongation at 72°C for 60 seconds, repeated for 35 cycles, and a final extension at 72°C for 5 minutes.[17] The PCR cyclic parameters for oqxAB were as follows: initial denaturation at 95°C for 15 minutes; 30 cycles of 94°C for 30 seconds, 63°C for 90 seconds, and 72°C for 90 seconds, followed by a final extension at 72°C for 10 minutes. The PCR conditions used for qepA were as follows: initial denaturation at 96°C for 1 minute, followed by 30 cycles of amplification at 96°C for 1 minute, annealing at 60°C for 1 minute, extension at 72°C for 1 minute, and the final extension step was at 72°C for 5 minutes.[18] The primers used is given in ►Table 1.[16-18] The PCR by-product was examined by electrophoresis in agarose gel containing ethidium bromide and visualized by gel documentation system.
| PMQR gene | Primers | Product size | Reference |
|---|---|---|---|
| qnrA | 5′-TCAGCAAGAGGATTTCTCA-3′ 5′-GGCAGCACTATTA CTCCCA-3′ |
516 | [16] |
| qnrB | 5′-GATCGTGAAAGCCAGAAAGG3′ 5′-ACGATG CCTGGTAGTTGTCC-3′ |
469 | [16] |
| qnrS | 5′-ACGACATTCGTCAACTGCAA-3′ 5′-TAAATTGGCACCCTGTAGGC-3′ |
417 | [16] |
| acc(6')-Ib-cr | 5′-TTGGAAGCGGGGACGGAM-3′ 5′-ACACGGCTGGACCATA -3′ |
260 | [17] |
| oqxAB | 5′-CCGCACCGATAAATTAGTCC-3′ 5′-GGCGAGGTTTTGATAGTGGA-3′ |
313 | [18] |
| qepA | 5-GCA GGT CCA GCA GCG GGT AG-3 5-CTT CCT GCC CGA GTA TCG TG-3 |
218 | [18] |
Abbreviation: PMQR, plasmid-mediated quinolone resistance.
DNA Sequencing
The PCR positive amplicons were sequenced at SciGenome Labs Pvt, Ltd., India and analyzed with BLAST tools (www.ncbi.nim.nih.gov). The assigned GenBank accession number for the submitted sequences are: (1) MH709266 (qnrA); (2) KY130487 (qnrB); (3) KY130488 (qnrS); (4) MH709269 (acc(6')-Ib-cr), and (5) MN273774 (oqxAB).
Conjugation
Conjugation experiments were performed for all PMQR positive isolates. Escherichia coli J53 AziR strain was used as the recipient and PMQR positive isolates as donor. The donor and recipient cells (0.5 mL each) in logarithmic phase were added to 3 mL of LB broth and incubated at 37°C overnight. Transconjugants were selected by plating on MacConkey agar plates containing sodium azide (100 µg/mL) and ciprofloxacin (0.5 µg/mL).[19] The transfer of PMQR genes in transconjugants was confirmed by PCR.
Incompatibility Grouping of Plasmid Encoding Resistance for PMQR Genes
Plasmid Inc group for the transconjugants was determined by PBRT. Five sets of multiplex PCR ([HI1, HI2, I1]; [X, L/M, N]; [FIA, FIB, W]; [YP FIC]; [A/C, T, FIIS]) and three simplex PCR (FrepB, K/B, B/O) were performed.[13] The primers employed is depicted in ►Table 2.[13]
| Replicon type | Primer sequence (5′–3′) | Amplicon size (bp) |
|---|---|---|
| HI1 | F-GGAGCGATGGATTACTTCAGTAC R-TGCCGTTTCACCTCGTGAGTA |
471 |
| HI2 | F-TTTCTCCTGAGTCACCTGTTAACAC R-GGCTCACTACCGTTGTCATCCT |
644 |
| I1 | F-CGAAAGCCGGACGGCAGAA R-TCGTCGTTCCGCCAAGTTCGT |
139 |
| X | F-AACCTTAGAGGCTATTTAAGTTGCTGAT R-TGAGAGTCAATTTTTATCTCATGTTTTAGC |
376 |
| L/M | F-GGATGAAAACTATCAGCATCTGAAG R-CTGCAGGGGCGATTCTTTAGG |
785 |
| N | F-GTCTAACGAGCTTACCGAAG R-GTTTCAACTCTGCCAAGTTC |
559 |
| FIA | F-CCATGCTGGTTCTAGAGAAGGTG R-GTATATCCTTACTGGCTTCCGCAG |
462 |
| FIB | F-GGAGTTCTGACACACGATTTTCTG R-CTCCCGTCGCTTCAGGGCATT |
308 |
| W | F-CCTAAGAACAACAAAGCCCCCG R-GGTGCGCGGCATAGAACCGT |
242 |
| Y | F-AATTCAAACAACACTGTGCAGCCTG R-GCGAGAATGGACGATTACAAAACTTT |
765 |
| P | F-CTATGGCCCTGCAAACGCGCCAGAAA R-TCACGCGCCAGGGCGCAGCC |
534 |
| FIC | F-GTGAACTGGCAGATGAGGAAGG R-TTCTCCTCGTCGCCAAACTAGAT |
262 |
| A/C | F-GAGAACCAAAGACAAAGACCTGGA R-ACGACAAACCTGAATTGCCTCCTT |
465 |
| T | F-TTGGCCTGTTTGTGCCTAAACCAT R-CGTTGATTACACTTAGCTTTGGAC |
750 |
| FIIS | F-CTGTCGTAAGCTGATGGC R-CTCTGCCACAAACTTCAGC |
270 |
| FrepB | F-TGATCGTTTAAGGAATTTTG R-GAAGATCAGTCACACCATCC |
270 |
| K/B | F-GCGGTCCGGAAAGCCAGAAAA R-TCTTTCACGAGCCCGCCAAA |
160 |
| B/O | F-GCGGTCCGGAAAGCCAGAAAA R-TCTGCGTTCCGCCAAGTTCGA |
159 |
Abbreviation: PCR, polymerase chain reaction.
Results
Antimicrobial Susceptibility Testing
All the study isolates were resistant to other fluoroquinolones—levofloxacin and ofloxacin. Resistance to other classes of antimicrobial agents was as follows: ceftazidime (86.9%), piperacillin/tazobactam (73.8%), imipenem (69.2%), and amikacin (63.8%). The MIC of ciprofloxacin ranged from 4 to greater than or equal to 256 µg/mL. The MIC50 and MIC90 values were 64 and greater than or equal to 256 µg/mL, respectively.
Detection of Efflux Pump Activity
Among 130 isolates, twofold reduction was evident in 46 (35.8%) and fourfold or more reduction was observed in 37 (28.4%). Fourfold was evident in 11 (12.9%), 8-fold in 5 (5.8%), 16-fold in 7 (8.2%), 32-fold in 3 (3.5%), and 128 fold in 2 (2.3%) among P. aeruginosa. In A. baumannii, 4-fold reduction was observed in one (2.2%) isolate, 8-fold in three (6.6%), 16-fold in two (4.4%), and 64-fold in three (6.6%), respectively (►Table 3).
| Organism (n = 130) | Fold reduction in MIC + CCCP (µg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | |
| Pseudomonas aeruginosa (n = 85) | 21 | 36 | 11 | 5 | 7 | 3 | 0 | 2 |
| Acinetobacter baumannii (n = 45) | 26 | 10 | 1 | 3 | 2 | 0 | 3 | 0 |
Abbreviations: CCCP, carbonyl-cyanide m-chlorophenylhydrazone; MIC, minimal inhibitory concentration.
Polymerase Chain Reaction
Among P. aeruginosa, qnr genes were detected in 36 (27.6%) isolates, of which 12 (14.1%) isolates harbored qnrB, 12 (14.1%) carried qnrS gene, and 9 (10.5%) isolates harbored both qnrB and qnrS genes. Among A. baumannii, qnrB was detected in two (4.4%) isolates and only one (2.2%) harbored both the qnrA and qnrS; 77.6% (66) of P. aeruginosa and 46.6% (21) of A. baumannii isolates harbored aac(6′)-Ib-cr gene; 3.5% (3) of P. aeruginosa and 2.2% (1) of A. baumannii isolates harbored oqxAB gene. qepA gene was not detected in any of the study isolates. The PMQR genes encountered is depicted in ►Table 4.
| PMQR genes | Pseudomonas aeruginosa (n = 85) | Acinetobacter baumannii (n = 45) | Total prevalence (n = 130) |
|---|---|---|---|
| aac(6′)-Ib-cr | 31 (36.4%) | 17 (37.7%) | 48 (36.9%) |
| oqxAB | 1 (1.1%) | 1 (2.2%) | 2 (1.5%) |
| qnrB + aac(6′)-Ib-cr | 12 (14.1%) | 2 (4.4%) | 14 (10.7%) |
| qnrS + aac(6′)-Ib-cr | 12 (14.1%) | 0 | 12 (9.2%) |
| qnrA + qnrS + aac(6′)-Ib-cr | 0 | 1 (2.2%) | 1 (0.7%) |
| qnrB + qnrS + aac(6′)-Ib-cr | 9 (10.5%) | 1 (2.2%) | 10 (7.6%) |
| qnrB + qnrS + oqxAB + aac(6′)-Ib-cr | 1 (1.1%) | 0 | 1 (0.7%) |
| oqxAB + aac(6′)-Ib-cr | 1 (1.1%) | 0 | 1 (0.7%) |
| Total | 67 (78.8%) | 22 (48.8%) | 89 (68.5%) |
Abbreviation: PMQR, plasmid-mediated quinolone resistance.
PMQR Gene Transfer and Distribution of Plasmid Replicons
In P. aeruginosa, 9.2% (12/130) were transferred successfully. All the 12 transconjugants were positive only for aac(6′)-Ib-cr gene. In A. baumannii, none of them was transferable.
The plasmid incompatibility types of the transconjugants were recognized by PBRT. Of the 12 transconjugants, 7 (58.3%) belonged to IncFII type plasmid replicon, 4 (33.3%) were IncA/C, and 1 (8.3%) IncFIC type.
Discussion
Fluoroquinolones are potent antibiotics active against a broad range of bacteria. The global increase in the prevalence of clinical strains with reduced susceptibility to fluoroquinolones constitutes a major concern.[20] The emergence of fluoroquinolone resistance among P. aeruginosa and A. baumannii presents a serious challenge in clinical management of bacterial infections.[21] In this study, antibiotic susceptibility testing revealed that all the test isolates were resistance to the other fluoroquinolones also: levofloxacin and ofloxacin. Resistance to other class of antibiotics was ceftazidime (86.9%), piperacillin/tazobactam (73.8%), imipenem (69.2%), and amikacin (63.8%). In this study, 32.9% (28) of P. aeruginosa and 37.7% (17) of A. baumannii isolates had an MIC of greater than or equal to 256 μg/mL to ciprofloxacin and similar observation has also been documented by Zaki et al.[22]
In this study, the MIC decrease factor value of fourfold and more reduction was evident in 28.4% (37/130) of isolates. In one isolate (4.5%) (P. aeruginosa), it resulted in loss of ciprofloxacin resistance thus reflecting a highly active efflux activity as evidenced by the decrease in MIC from 256 to 0.5 μg/mL on addition of CCCP inhibitor. Similar inhibition of efflux pump activity has been described previously.[23,24] Researchers in the United States, Iran, and Bahrain have observed nonsignificant twofold reduction in MIC on addition of efflux pump inhibitor CCCP in P. aeruginosa.[25-27] Helmy et al in their study reported significant efflux pump activity in A. baumannii and P. aeruginosa (46.1 and 41.1%).[28] Gomaa et al in Egypt recorded a high percentage of efflux pump-mediated resistance (77.8%) in A. baumanni.[29] In contrast, in South Africa, CCCP inhibitors did not affect MIC in A. baumanni.[24]
In this study, among qnr genes, 14.1% (12) were qnrB and 14.1% (12) were qnrS in P. aeruginosa which is a higher rate compared with a previous study from Egypt, which documented the presence of qnrB and qnrS genes in 1.8 and 2.7% of Pseudomonas spp.[18] In contrast, El-Badawy et al and Rafiq et al documented high prevalence of qnrS (79.5 and 24%) gene, respectively. qnrA and qnrB were not detected in any of their isolates of Pseudomonas spp.[30,31] Similar to the earlier study, qnrA gene was not detected in any of the isolates of P. aeruginosa in the present study. In China, a single isolate of P. aeruginosa with qnrA has been observed.[32] In many other studies, qnr determinants were not detectable in clinical isolates of P.aeruginosa.[33,34]
Yang et al examined the prevalence of qnr genes among 39 isolates of A. baumannii where 7.7% (3/39) isolates harbored qnrB and 2.6% (1/39) qnrS.[12] Hamed et al also reported the presence of qnrS gene in one isolate of A. baumannii.[35] Touati et al observed qnrA gene in only one isolate in their study.[36] In the present study, qnrB was encountered in two isolates singly. One isolate harbored qnrB and qnrS, while another carried both qnrA and qnrS.
In Brazil, a low prevalence of aac(6′)-Ib-cr gene (2.6%) was found in P. aeruginosa.[37] Studies from Turkey and Egypt reported a high prevalence 56.4 and 79.5% in P. aeruginosa, respectively. This is similar to the findings of the present study (66.9%).[38] In this study, only four (3%) isolates harbored oqxAB. Notably, qepA gene was not encountered. oqxAB and qepA genes were not identified in many other studies too.[39-41]
Conjugation experiments demonstrated that in 14.1% (12/85) of P. aeruginosa, PMQR determinants were successfully transferred and all the transconjugants harbored the aac(6′)-Ib-cr gene. In A. baumannii, none of them was transferable. Jiang et al in their study documented that in 33.3% of nonfermenting gram negative bacteria (NFGNB), the transconjugants harbored the same PMQR determinants as their donors.[42] In this study, more than one half of PMQR determinants, 59.2% were nonconjugative, and this suggests that these genes may be of chromosomal location. Among the PMQR genes, high incidence of aac(6′)-Ib-cr (66.9%) was encountered and when conjugated, the transferability rate was 100% for this gene. This emphasizes that aac(6′)-Ib-cr gene plays a major role in mediating fluoroquinolone resistance. In the present study, of the 12 transconjugants, 33.3% belonged to IncA/C type plasmid replicon. In Nigeria, IncF plasmid harboring aac(6′)-Ib-cr gene has been described in P. aeruginosa.[43] A recent study in Argentina has demonstrated plasmid IncR group in P. aeruginosa.[44]
In this study, the prevalence rate of PMQR determinants is (68.5%), which is higher than the rates in China (1.7%), Egypt (4.5%), and Nigeria (61%).[18,42,45] However, increasing rates of fluoroquinolone resistance have limited the treatment option. The approach of combined antibiotic therapies is an alternative to this phenomenon.[46]
The ciprofloxacin resistance isolates which were negative for PMQR genes in our study may probably harbor the chromosomal mutation genes (gyrA, gyrB, parC, and parE). These genes were not looked for in the present study.
Conclusion
Plasmid-mediated fluoroquinolone resistance is encountered in (78.8%) of P. aeruginosa, while in A. baumannii, it is present in a proportion of 48.8% of clinical isolates. Single clinical isolate can harbor multiple PMQR genes. Plasmid-mediated efflux fluoroquinolone resistance is responsible only for a small proportion of resistance to fluoroquinolone in clinical isolates of P. aeruginosa and A. baumannii. Of the plasmid efflux pump genes, only oqxAB is present in 3% of isolates. It is reasonable to assume that of the plasmid-mediated resistance, aac(6′)-Ib-cr is primarily responsible for mediating a major proportion of resistance to fluoroquinolones. IncFII is the predominant plasmid type followed by IncA/C and IncFIC type.
Conflict of Interest
None declared.
Funding
This study is funded by Department of Science & Technology (DST) under Women Scientists Scheme (WOS-A).
References
- Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother. 2003;47(07):2242-2248.
- [CrossRef] [PubMed] [Google Scholar]
- Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43(2, Suppl 2):S49-S56.
- [CrossRef] [PubMed] [Google Scholar]
- Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;1354(01):12-31.
- [CrossRef] [PubMed] [Google Scholar]
- Quinolone resistance from a transferable plasmid. Lancet. 1998;351(9105):797-799.
- [CrossRef] [PubMed] [Google Scholar]
- The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006;6(10):629-640.
- [CrossRef] [PubMed] [Google Scholar]
- New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother. 2007;51(09):3354-3360.
- [CrossRef] [PubMed] [Google Scholar]
- Plasmid-mediated quinolone resistance. Microbiol Spectr. 2014;2(05):10.
- [CrossRef] [PubMed] [Google Scholar]
- Contribution of OqxAB efflux pumps to quinolone resistance in extended-spectrum-β-lactamase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2013;68(01):68-73.
- [CrossRef] [PubMed] [Google Scholar]
- Plasmid-mediated quinolone resistance: an update. J Infect Chemother. 2011;17(02):149-182.
- [Google Scholar]
- High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6′)-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. Antimicrob Agents Chemother. 2008;52(12):4268-4273.
- [CrossRef] [PubMed] [Google Scholar]
- Detection of plasmid-mediated quinolone resistance determinants and the emergence of multidrug resistance in clinical isolates of Shigella in SiXian area, China. Diagn Microbiol Infect Dis. 2013;75(03):327-329.
- [CrossRef] [PubMed] [Google Scholar]
- Detection of the plasmid-mediated quinolone resistance determinants in clinical isolates of Acinetobacter baumannii in China. J Chemother. 2016;28(05):443-445.
- [CrossRef] [PubMed] [Google Scholar]
- Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005;63(03):219-228.
- [CrossRef] [PubMed] [Google Scholar]
- Performance Standards for Antimicrobial Susceptibility Testing. M100. (27th). Wanye (PA): Clinical and Laboratory Standards Institute; 2017.
- [Google Scholar]
- Effect of efflux pump inhibitor carbonyl cyanide 3-chlorophenylhydrazone on the minimum inhibitory concentration of ciprofloxacin in Acinetobacter baumannii clinical isolates. Jundishapur J Microbiol. 2014;7(01):e8691.
- [CrossRef] [PubMed] [Google Scholar]
- qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother. 2006;50(08):2872-2874.
- [CrossRef] [PubMed] [Google Scholar]
- Allele-specific polymerase chain reaction (PCR) for rapid detection of the aac(6′)-Ib-cr quinolone resistance gene. Int J Antimicrob Agents. 2010;36(05):476-477.
- [CrossRef] [PubMed] [Google Scholar]
- Plasmid mediated quinolone resistance determinants among nosocomial clinical Pseudomonas aeruginosa isolates. Int J Curr Microbiol Appl Sci. 2017;6(01):42-50.
- [CrossRef] [Google Scholar]
- Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother. 2003;47(07):2242-2248.
- [CrossRef] [PubMed] [Google Scholar]
- Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis. 2005;18(04):306-313.
- [CrossRef] [PubMed] [Google Scholar]
- Molecular study of quinolone resistance determining regions of gyrA gene and parC genes in clinical isolates of Acintobacter baumannii resistant to fluoroquinolone. Open Microbiol J. 2018;12:116-122.
- [CrossRef] [PubMed] [Google Scholar]
- Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother. 2006;58(06):1274-1278.
- [CrossRef] [PubMed] [Google Scholar]
- Genomic and phenotypic characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Durban, South Africa. PLoS One. 2017;12(06):e0178888.
- [CrossRef] [PubMed] [Google Scholar]
- Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev. 2012;36(02):340-363.
- [CrossRef] [PubMed] [Google Scholar]
- Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran. J Infect Dev Ctries. 2016;10(06):600-604.
- [CrossRef] [PubMed] [Google Scholar]
- Detection of overexpression of efflux pump expression in fluoroquinolone-resistant Pseudomonas aeruginosa isolates. Int J Appl Basic Med Res. 2020;10(01):37-42.
- [CrossRef] [PubMed] [Google Scholar]
- Different phenotypic and molecular mechanisms associated with multidrug resistance in Gram-negative clinical isolates from Egypt. Infect Drug Resist. 2017;10:479-498.
- [CrossRef] [PubMed] [Google Scholar]
- Phenotypic and genotypic detection of some antimicrobial resistance mechanisms among multidrug-resistant Acinetobacter baumannii isolated from immunocompromised patients in Egypt. Egypt J Med Microbiol. 2014;23(04):99-111.
- [CrossRef] [Google Scholar]
- Investigation of six plasmid-mediated quinolone resistance genes among clinical isolates of pseudomonas: a genotypic study in Saudi Arabia. Infect Drug Resist. 2019;12:915-923.
- [CrossRef] [PubMed] [Google Scholar]
- Determination of Qnr allele frequencies in fluoroquinolone resistant Pseudomonas aeruginosa isolated from burn wounds. J Pak Med Assoc. 2019;69(02):250-252.
- [Google Scholar]
- Prevalence and fluoroquinolone resistance of Pseudomonas aeruginosa in a hospital of South China. Int J Clin Exp Med. 2015;8(01):1386-1390.
- [Google Scholar]
- Investigation of plasmid-mediated quinolone resistance among isolates obtained in a Turkish intensive care unit. Jpn J Infect Dis. 2008;61(04):310-312.
- [CrossRef] [PubMed] [Google Scholar]
- Investigation of plasmid-mediated quinolone resistance in Pseudomonas aeruginosa strains isolated from cystic fibrosis patients [in Turkish] Mikrobiyol Bul. 2011;45(04):602-608.
- [Google Scholar]
- Multiple mechanisms contributing to ciprofloxacin resistance among Gram negative bacteria causing infections to cancer patients. Sci Rep. 2018;8(01):12268.
- [CrossRef] [PubMed] [Google Scholar]
- First report of qnrB-producing Enterobacter cloacae and qnrA-producing Acinetobacter baumannii recovered from Algerian hospitals. Diagn Microbiol Infect Dis. 2008;60(03):287-290.
- [CrossRef] [PubMed] [Google Scholar]
- Clinical and molecular epidemiology of multidrug-resistant P. aeruginosa carrying aac(6′)-Ib-cr, qnrS1 and blaSPM genes in Brazil. PLoS One. 2016;11(05):e0155914.
- [CrossRef] [PubMed] [Google Scholar]
- Investigation of plasmid-mediated quinolone resistance in Pseudomonas aeruginosa clinical isolates. Indian J Med Microbiol. 2014;32(03):285-289.
- [CrossRef] [PubMed] [Google Scholar]
- The first report of CMY, aac (6′)-Ib and 16S rRNA methylase genes among Pseudomonas aeruginosa isolates from Iran. Arch Pediatr Infect Dis. 2013;1(03):109-112.
- [CrossRef] [Google Scholar]
- Detection of plasmid-mediated quinolone resistance determinants in clinical non-fermentative bacteria and ciprofloxacin sensitive Enterobacteriaceae strains. Dis Surveill. 2014;29(02):130-135.
- [Google Scholar]
- Prevalence of resistance to aminoglycosides and fluoroquinolones among Pseudomonas aeruginosa strains in a University Hospital in Northeastern Poland. Braz J Microbiol. 2015;45(04):1455-1458.
- [CrossRef] [PubMed] [Google Scholar]
- Emergence of plasmid-mediated quinolone resistance genes in clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa in Henan, China. Diagn Microbiol Infect Dis. 2014;79(03):381-383.
- [CrossRef] [PubMed] [Google Scholar]
- Dissemination of IncF plasmids carrying beta-lactamase genes in Gram-negative bacteria from Nigerian hospitals. J Infect Dev Ctries. 2013;7(05):382-390.
- [CrossRef] [PubMed] [Google Scholar]
- Full characterization of an IncR plasmid harboring qnrS1 recovered from a VIM-11-producing Pseudomonas aeruginosa. Rev Argent Microbiol. 2020;52(04):298-304.
- [CrossRef] [PubMed] [Google Scholar]
- Distribution of plasmid-mediated quinolone resistance in Gram-negative bacteria from a tertiary hospital in Nigeria. Indian J Pathol Microbiol. 2016;59(03):322-326.
- [CrossRef] [PubMed] [Google Scholar]
- Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis. 2014;59(6, Suppl 6):S367-S373.
- [CrossRef] [PubMed] [Google Scholar]
